Recursion Pharmaceuticals, Inc. launches an IPO.

IPO of Recursion Pharmaceuticals, Inc. (RXRX) will take place on April 15, 2021. Recursion Pharmaceuticals is a clinical stage biotechnology company dedicated to deciphering biology by integrating technological innovations in biology and chemistry. Recursion OS is an integrated, layered system for generating, analyzing and extracting information from biological and chemical datasets. Every program at Recursion Pharmaceuticals is a Recursion OS product. Currently, the company has 37 different programs in development, 10 of which are key at the moment (sheet 5 - product development stages).

Estimated valuation of the company after the IPO will be $2.4 billion.

The listed bookrunners of the IPO are Goldman Sachs, JP Morgan, BofA Securities, SVB Leerink, Allen & Company and KeyBanc Capital Markets.